Prostate Cancer & PSA Screening

See Benign Prostatic Hyperplasia for the non-malignant differential. Left in-review — the RACGP Red Book PSA screening position below is a genuine, significant, and still-evolving guideline change; PCFA-endorsed updated clinical guidelines were expected in late 2025.

Epidemiology

Prostate cancer is the most common malignancy in Australian men and the second most common cause of cancer death. Risk rises steeply with age — rare before 50, and up to 80% of men have histological evidence of carcinoma by age 80 (most of it clinically insignificant). Lifetime risk of a diagnosis by age 85 is around 1 in 5; lifetime risk of dying from it is around 1 in 25. Five-year survival at diagnosis is ~92–95%.

Risk factors: family history (a first-degree relative diagnosed before 65 carries the strongest signal — see the screening table below for how this now changes the testing age), a first-degree relative with a BRCA1/2 mutation.

PSA screening — the guideline position has reversed

This is the single biggest change since the original notes were written. The RACGP Guidelines for preventive activities in general practice (the Red Book) completely reversed its PSA screening position between the 9th edition (2016) and the 10th edition (2024):

Edition	Men at average risk	Men at high risk (family history)
9th (2016)	Not recommended	Not recommended
10th (2024)	Offer from age 50, if well-informed and interested	Offer from age 45 (one first-degree relative), or 40 (three first-degree relatives)

The 2016 “not recommended” position leaned on the US PLCO trial, which showed no mortality benefit — but had major protocol contamination (much of its control group was also PSA tested). The European ERSPC trial, with much less contamination, showed a significant prostate-cancer mortality reduction with screening, and its 16-year follow-up data helped drive the 2024 revision.

Current practice points (10th edition Red Book + current MBS criteria):

• Offer PSA testing from age 50 after discussing risks and benefits; from 45 with one affected first-degree relative; from 40 with three affected first-degree relatives.
• If total PSA < 3.0 ng/mL: repeat in 2 years (MBS funds testing every 23 months at this level, reflecting evidence that a mortality benefit only emerges after years of follow-up — annual testing is no longer the standard).
• If total PSA > 3.0 ng/mL: repeat in 1–3 months. If still elevated, refer to urology for review and a prostate MRI.
• Do not offer PSA testing if life expectancy is < 7 years — limited mortality benefit.
• Men taking exogenous anabolic steroids should be considered an at-risk group (not because the drugs themselves cause prostate cancer, but because they may stimulate its growth).
• Prostate cancer, once found, does not always need treatment — active surveillance with risk minimisation is recommended for low-risk (Grade Group 1 / ISUP 1) disease.

Why the harms calculus changed: the 2016 position was driven by overdiagnosis/ overtreatment concerns (per 1000 men screened: roughly one life saved, but ~0.5 deaths from treatment complications, ~87 unnecessary biopsies, ~28 biopsy complications, 7–10 men left with impotence or incontinence). Since then, mpMRI now triages men before biopsy, directing biopsy only to those at risk of clinically significant disease and reducing overdiagnosis of insignificant cancers; transperineal biopsy has largely replaced transrectal biopsy, substantially cutting biopsy-related sepsis risk; and active surveillance has become a well-evidenced, mainstream option (below) — together shifting the risk/benefit balance enough to justify the reversal. mpMRI attracts a Medicare rebate (for men under 70 with two PSA levels >3.0 ng/mL within 3 months and a free/total PSA ratio under 25%) when ordered by a urologist.

RACGP’s own public messaging remains more cautious than the Red Book table above taken in isolation — it emphasises this is a shared decision-making conversation, not a call to proactively recruit asymptomatic men, and that PSA testing should stay an informed choice rather than routine screening. Locally tailored factsheets on the Australian prostate cancer burden are available to support that conversation.

Presentation

Usually asymptomatic and detected via a rising PSA or incidentally on histology after a TURP for presumed BPH. When symptomatic:

• Rapidly progressive lower urinary tract symptoms, acute urinary retention
• Bone pain (pelvis, vertebrae) from metastases, pathological fracture
• Haematuria, weight loss, uraemia, tiredness, perineal pain

Examination: DRE is usually normal even with cancer present (most cancer arises in the peripheral zone) but may reveal a nodule, firm irregular area, asymmetry, or loss of the median sulcus.

Diagnosis and staging

• PSA is affected by BPH, recent instrumentation/catheterisation, ejaculation, and infection — interpret in that context. Age-specific reference ranges exist. In the moderately elevated 4–10 ng/mL range, a lower free/total PSA ratio (< 8–25% depending on the assay/context) favours cancer over BPH, since BPH tends to release free PSA in variable “showers” while cancer produces a steadier bound fraction.
• mpMRI before biopsy is now standard (see above), reported on the PI-RADS scale, used to target biopsies and can support avoiding biopsy altogether in low-suspicion scans.
• Transperineal biopsy, usually with imaging fusion, is now preferred over the older transrectal approach for its much lower sepsis risk.
• Grading: Gleason pattern scores (2–10, with the two most common patterns summed) are now reported alongside the simpler ISUP/Grade Group system (1–5) — Grade Group 1 corresponds to Gleason 3+3, the threshold for the lowest-risk, active-surveillance-eligible category.
• Staging combines clinical/imaging tumour stage (T1–T4), nodal status (N), metastasis (M), PSA, and grade group. PSMA PET/CT has become the standard staging investigation for intermediate/high-risk disease and for detecting recurrence after treatment, largely superseding bone scan/CT in these settings.

Management

Treatment intensity is matched to grade group, stage, PSA, age, comorbidity, and patient preference — from active surveillance through to radical treatment.

Active surveillance vs watchful waiting

Both are conservative strategies, but with different intent — worth distinguishing clearly:

	Active surveillance	Watchful waiting
Intent	Curative	Palliative
Follow-up	Predefined schedule (PSA/DRE 3–6 monthly, interval MRI, rebiopsy)	Patient-specific, driven by symptoms
Typical life expectancy	> 10 years	< 10 years
Aim	Minimise treatment toxicity without compromising survival	Minimise treatment toxicity/symptom burden
Eligible disease	Mostly low-risk	Any stage

Active surveillance is now the recommended strategy for low-risk disease (PSA < 10, Grade Group 1, clinical stage T1–T2a) and, in appropriately counselled patients, selected favourable intermediate-risk disease (low-volume Grade Group 2 — fewer than three positive cores, < 50% core involvement, no cribriform pattern/intraductal carcinoma), whose 10-year metastasis-free and cancer-specific survival are close to low-risk figures. Randomised evidence shows no survival benefit from immediate radical treatment of low-risk disease over surveillance with treatment held for the minority who progress — while avoiding the morbidity of treatment for the rest. Escalation to active treatment is triggered by grade progression, growth on biopsy, PSA doubling time under 3 years, or patient preference.

Definitive and systemic treatment

• Localised disease: radical prostatectomy (increasingly robot-assisted, which has improved perioperative safety) or radiotherapy, chosen on patient/disease factors — long-term outcomes between surgery, radiotherapy, and active monitoring are broadly similar once the harms of treatment are weighed against the modest cancer-specific survival difference.
• Metastatic/advanced disease — androgen deprivation therapy (ADT) remains the backbone (orchidectomy, LHRH agonists such as goserelin, or antiandrogens), but the field has moved well beyond ADT alone: androgen receptor pathway inhibitors (abiraterone, enzalutamide, apalutamide, darolutamide) are now added earlier — including in high-risk non-metastatic and newly metastatic hormone-sensitive disease, not just after castration resistance develops — and meaningfully improve survival over ADT alone.
• For metastatic castration-resistant disease, PSMA-targeted radioligand therapy (lutetium-177 PSMA-617) is now PBS-listed for PSMA-avid disease, alongside the androgen receptor pathway inhibitors above.
• Complications of treatment: erectile dysfunction and incontinence remain the major quality-of-life costs of radical treatment — a central reason conservative strategies are preferred wherever oncologically appropriate. Bladder neck stenosis and urethral stricture can also follow any prostate cancer treatment and are usually managed with simple endoscopic intervention.